Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas5.73 B5.37 B5.41 B6.18 B7.1 B7.05 B6.96 BPesquisa e desenvolvimento4.21 B6.32 B4.43 B4.78 B5.96 B7.27 B7.5 BLucro operacional9.14 B7.64 B9.57 B7.9 B7.26 B9.08 B10.57 BLucro não operacional, total256 M259 M-814 M2.83 B506 M2.65 B1.21 BDespesa com juros, líquida de juros capitalizados1.26 B1.2 B1.41 B2.88 B3.15 B2.75 B2.69 BReceitas não operacionais, líquidas das despesas com juros256 M259 M-814 M2.83 B506 M-104 M-1.48 BReceitas/despesas incomuns———————Lucro antes dos impostos8.13 B6.7 B6.46 B7.86 B4.61 B8.98 B16.55 BParticipação no lucro——-891 M-11 M10 M——Impostos869 M808 M794 M1.14 B519 M1.26 B1.29 BParticipação de minoritários———————Outras receitas/despesas após impostos195 M229 M176 M-563 M8 M-149 M-132 MLucro líquido antes das operações descontinuadas7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.8 BOperações descontinuadas———————Lucro líquido7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.8 BAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.8 BLucro básico por ação12.410.3412.1812.567.6214.3314.48Lucro diluído por ação12.3110.2812.1112.497.5614.2314.37Número médio de ações básicas586 M570 M538 M535 M537 M538 M—Ações diluídas590 M573 M541 M538 M541 M542 M—EBITDA12.74 B11.04 B12.98 B11.97 B12.85 B14.25 B15.46 BEBIT9.14 B7.64 B9.57 B7.9 B7.26 B9.08 B10.57 BCusto da receita6.16 B6.45 B6.41 B8.45 B12.86 B12.04 B11.81 BOutros componentes do custo———————Amortização e depreciação (fluxo de caixa)3.6 B3.4 B3.42 B4.07 B5.59 B5.17 B4.9 B
Amgen Inc. - Common Stock
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.